A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

NCT06747156 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Diseases

Interventions

DRUG: ABO2203 Injection

Sponsor

Ruijin Hospital

Collaborators

[object Object]